SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

SLS SELLAS Life Sciences Group Inc.

Closed New Year's Day 12-31 16:00:00 EST

3.77

+0.46

+13.90%

盘后3.86

+0.09+2.39%

19:59 EST

High3.84	Low3.40	Vol23.23M
Open3.46	D1 Closing3.31	Amplitude13.29%
Mkt Cap535.34M	Tradable Cap535.34M	Total Shares142.00M
T/O84.21M	T/O Rate16.36%	Tradable Shares142.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"SLS","market":"US","secType":"STK","nameCN":"SELLAS Life Sciences Group Inc.","latestPrice":3.77,"timestamp":1767214800000,"preClose":3.31,"halted":0,"volume":23234890,"hourTrading":{"tag":"盘后","latestPrice":3.86,"preClose":3.77,"latestTime":"19:59 EST","volume":461479,"amount":1797372.8381,"timestamp":1767229191629},"delay":0,"floatShares":142000000,"shares":142000000,"eps":-0.281267,"marketStatus":"Closed New Year's Day","change":0.46,"latestTime":"12-31 16:00:00 EST","open":3.46,"high":3.84,"low":3.4,"amount":84207437.58113399,"amplitude":0.132931,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.281267,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1767344400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":3.31,"preHourTrading":{"tag":"盘前","latestPrice":3.49,"preClose":3.31,"latestTime":"09:29 EST","volume":237747,"amount":816292.7699958,"timestamp":1767191353434},"postHourTrading":{"tag":"盘后","latestPrice":3.86,"preClose":3.77,"latestTime":"19:59 EST","volume":461479,"amount":1797372.8381,"timestamp":1767229191629},"volumeRatio":1.7698199983668061,"optionData":{"bulkOrders":[{"symbol":"SLS","call":true,"expireDate":1771563600000,"strike":"2.0","timestamp":1767193914374,"price":1.52,"volume":27889,"amount":4239128,"type":"-"},{"symbol":"SLS","call":true,"expireDate":1771563600000,"strike":"2.5","timestamp":1767193914374,"price":1.07,"volume":23000,"amount":2461000,"type":"+"}]},"impliedVol":2.0619,"impliedVolPercentile":0.776},"requestUrl":"/m/hq/s/SLS","defaultTab":"news","newsList":[{"id":"2595758618","title":"SELLAS Life Sciences Stock Is Surging Higher: What's Going On?","url":"https://stock-news.laohu8.com/highlight/detail?id=2595758618","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595758618?lang=en_us&edition=fundamental","pubTime":"2025-12-30 04:40","pubTimestamp":1767040800,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group climbs higher after a premarket drop, reversing course as investors seem to react to new trial‑related updates.","market":"hk","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/12/29/Stock-Market-Trading-Graph-And-Financial_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/12/29/Stock-Market-Trading-Graph-And-Financial_1.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/trading-ideas/movers/25/12/49619904/sellas-life-sciences-stock-is-surging-higher-whats-going-on","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/trading-ideas/movers/25/12/49619904/sellas-life-sciences-stock-is-surging-higher-whats-going-on","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2595737669","title":"SELLAS Life Sciences Group Up Nearly 17%, on Track for Highest Close Since February 2023 -- Data Talk","url":"https://stock-news.laohu8.com/highlight/detail?id=2595737669","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595737669?lang=en_us&edition=fundamental","pubTime":"2025-12-30 02:57","pubTimestamp":1767034620,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group, Inc.  is currently at $3.36, up $0.49 or 16.9%. --Would be highest close since Feb. 23, 2023, when it closed at $3.69. --On pace for largest percent increase since Jan. 31, 2025, when it rose 21.8%. --Currently up seven consecutive days; up 59% over this period. --Longest winning streak since Dec. 16, 2025, when it rose for seven straight trading days. --Up 107.1% month-to-date; on pace for best month since Oct. 2022, when it rose 131.68%. --Up 222.6% year-to-date; on pace for best year since 2013, when it rose 224.18%. --Down 100% from its all-time closing high of $335363.30 on March 13, 2008. --Up 237.83% from 52 weeks ago , when it closed at $0.99. --Traded as high as $3.40; highest intraday level since Feb. 23, 2023, when it hit $3.85","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2595735394","title":"Sellas Life Sciences Says 72 Deaths Have Occurred in Phase 3 Acute Myeloid Leukemia Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2595735394","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595735394?lang=en_us&edition=fundamental","pubTime":"2025-12-29 22:15","pubTimestamp":1767017753,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences  said Monday it was informed that 72 deaths have occurred in its phase 3 Regal trial, currently evaluating its Galinpepimut-S therapy candidate in patients with acute myeloid leukemia after second complete remission.The company said that the Regal trial is an overall survival study, and a final analysis will be undertaken only after 80 deaths have been registered, which was previously expected to occur by the end of the year.Sellas said it remains blinded to all efficacy and survival data outcomes of the trial and will announce the 80th death event when it occurs.Shares of the company were down 6% in recent Monday premarket activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK7104","SLS.AU","SLS"],"gpt_icon":0},{"id":"2595738497","title":"Sellas Life Sciences Reports Progress in Phase 3 REGAL Trial of Galinpepimut-S for AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2595738497","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595738497?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:35","pubTimestamp":1767015311,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group Inc. announced an update on its ongoing Phase 3 REGAL trial evaluating Galinpepimut-S  as a potential maintenance therapy in patients with acute myeloid leukemia  following second complete remission. As of December 26, 2025, 72 events have occurred in the study, according to the contract research organization managing the trial. The company remains blinded to all efficacy and survival outcomes, and no analyses have been performed. The final analysis will be conducted once the 80th event occurs, at which time results will be announced. Results from the trial have not yet been presented.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL4KzXmz:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014039.USD","SG9999014013.SGD","LU2210150020.SGD","SG9999014021.USD","SLS","IE00BGHQF748.EUR","IE00B64PRP62.GBP","LU0314104364.USD","NDAQ","SG9999014005.SGD","BK4112","IE00B3QW5Z07.USD","LU2095319765.USD","LU2210149790.SGD","IE00BKPKM429.USD","BK4139","BK4585","BK4588"],"gpt_icon":0},{"id":"2595462738","title":"Sellas Life Sciences Provides Update on Pivotal Phase 3 Regal Trial of Galinpepimut-S (Gps) in Acute Myeloid Leukemia (Aml)","url":"https://stock-news.laohu8.com/highlight/detail?id=2595462738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595462738?lang=en_us&edition=fundamental","pubTime":"2025-12-29 21:35","pubTimestamp":1767015300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nTUA9ZJ3KN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"1166741806","title":"New NASA Chief Vows: Moon Return Within Trump's Term","url":"https://stock-news.laohu8.com/highlight/detail?id=1166741806","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166741806?lang=en_us&edition=fundamental","pubTime":"2025-12-28 08:00","pubTimestamp":1766880038,"startTime":"0","endTime":"0","summary":"The new Administrator of the National Aeronautics and Space Administration (NASA), Jared Isaacman, has stated that the United States will return to the moon during Trump's second term, which is...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","DXYZ","BK4139","UFO"],"gpt_icon":1},{"id":"1120522495","title":"Key Reasons Behind Jared Isaacman's Appointment as NASA Administrator and Analysis of the Athena Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=1120522495","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120522495?lang=en_us&edition=fundamental","pubTime":"2025-12-21 15:11","pubTimestamp":1766301068,"startTime":"0","endTime":"0","summary":"The nomination of Jared Isaacman as NASA Administrator by former President Trump in November 2025, later confirmed by the Senate (67-30 vote), was driven by three key factors: his commercial space...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AI","DXYZ","UFO","BK4551","SINA","BK4528","BK4139","SLS","BK4587","BK4543","BK4023","BK4585","BK4588"],"gpt_icon":1},{"id":"2590533441","title":"SELLAS Life Sciences Group (SLS): Valuation Check After Positive Phase 2 Data for SLS009 in AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2590533441","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2590533441?lang=en_us&edition=fundamental","pubTime":"2025-12-10 21:29","pubTimestamp":1765373348,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Group (SLS) is back on traders radar after announcing positive Phase 2 data for SLS009 in combination therapy for tough to treat acute myeloid leukemia patients with myelodysplastic changes.\nSee our latest analysis for SELLAS Life Sciences Group.\nThe upbeat Phase 2 readout has added fresh fuel to a stock that was already in motion, with a 1 day share price return of 4.40 percent and year to date share price return of 77.57 percent. The 1 year total shareholder return of...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-valuation-check-after-positiv","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-sls/sellas-life-sciences-group/news/sellas-life-sciences-group-sls-valuation-check-after-positiv","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["SLS.AU","SLS","BK4139","BK7104"],"gpt_icon":0},{"id":"2589362143","title":"Sellas Life Says Phase 2 Study of Cancer Combination Treatment Shows 'Clinically Meaningful' Activity; Shares Up Pre-Bell","url":"https://stock-news.laohu8.com/highlight/detail?id=2589362143","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589362143?lang=en_us&edition=fundamental","pubTime":"2025-12-08 17:45","pubTimestamp":1765187112,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group  said Sunday that results of an ongoing phase 2 study of SLS009 in combination with azacitidine and venetoclax showed \"clinically meaningful\" activity in patients with relapsed or refractory acute myeloid leukemia, a type of cancer.Among the 35 evaluable patients, the overall response rate was 46%. Patients harboring ASXL1 or TP53 mutations achieved response rates of 48% and 57%, respectively. The company said the median overall survival was \"exceedingly higher\" than the expected 2.6 months in this patient population.The results didn't show any dose-limiting toxicities or treatment-related deaths, and the combination was well tolerated, according to Sellas.The company's shares were up 8.1% in recent premarket activity Monday.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7104","SLS","BK4139","SLS.AU"],"gpt_icon":0},{"id":"2589809491","title":"Sellas Life Sciences Announces Positive Phase 2 Results for SLS009 Combination in Relapsed AML","url":"https://stock-news.laohu8.com/highlight/detail?id=2589809491","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589809491?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:00","pubTimestamp":1765148413,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group Inc. announced positive results from its ongoing Phase 2 study evaluating SLS009, a selective CDK9 inhibitor, in combination with azacitidine  and venetoclax  for patients with relapsed or refractory acute myeloid leukemia with myelodysplastic syndrome-related changes  following prior VEN-based treatment. The results, presented at the 67th American Society of Hematology  Annual Meeting in December 2025, showed a 46% overall response rate across all cohorts and a 58% overall response rate in patients with one prior line of therapy. The combination was reported to be safe and feasible, with no dose-limiting toxicities observed. The company plans to expand the study to evaluate SLS009 plus AZA/VEN in newly diagnosed AML with high-risk features in the first quarter of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated conten","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251207:nNDL8SKKlH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NDAQ","IE00BKPKM429.USD","SLS","LU2095319765.USD","IE00BGHQF748.EUR","SG9999014021.USD","SG9999014013.SGD","BK4112","BK4585","BK4139","IE00B64PRP62.GBP","LU2210149790.SGD","LU0314104364.USD","SG9999014005.SGD","LU2210150020.SGD","IE00B3QW5Z07.USD"],"gpt_icon":0},{"id":"2589809404","title":"SELLAS Life Sciences Presents Positive Phase 2 Data of SLS009 in Combination with AZA/VEN in Relapsed/Refractory AML-MR at ASH 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2589809404","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2589809404?lang=en_us&edition=fundamental","pubTime":"2025-12-08 07:00","pubTimestamp":1765148400,"startTime":"0","endTime":"0","summary":"SLS009 in combination with AZA/VEN achieved a 46% overall response rate across all cohorts, a 58% overall response rate in patients with one prior line of therapy, and encouraging survival outcomes in","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/12/07/3201154/0/en/SELLAS-Life-Sciences-Presents-Positive-Phase-2-Data-of-SLS009-in-Combination-with-AZA-VEN-in-Relapsed-Refractory-AML-MR-at-ASH-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ASH","LU2463526074.USD","SLS","BK4109","BK4139"],"gpt_icon":0},{"id":"2585145753","title":"Director Katherine Bach Kalin Acquires Common Shares of Sellas Life Sciences Group Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2585145753","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2585145753?lang=en_us&edition=fundamental","pubTime":"2025-11-21 21:45","pubTimestamp":1763732749,"startTime":"0","endTime":"0","summary":"Katherine Bach Kalin, Director at Sellas Life Sciences Group Inc., has reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 21, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251121:nNDL1YC4d5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Director Katherine Bach Kalin Acquires Common Shares of Sellas Life Sciences Group Inc","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2584924141","title":"SELLAS Life Sciences Q3 Net Income USD -6.791 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2584924141","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584924141?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:28","pubTimestamp":1763573296,"startTime":"0","endTime":"0","summary":"Nov 12 (Reuters) - SELLAS Life Sciences Q3 operating expenses USD 7.083 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 12-NOV-202521:01:00.197 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD2gJBXF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2583834875","title":"SELLAS Life Sciences Q3 net loss narrows to $6.8 mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2583834875","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583834875?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:28","pubTimestamp":1762982880,"startTime":"0","endTime":"0","summary":"SELLAS Life Sciences Q3 net loss narrows to $6.8 mlnOverviewSELLAS Q3 net loss narrows to $6.8 mln from $7.1 mln a year agoCompany's cash position strengthened by $29.1 mln from warrant exercises in O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nL1N3WO13J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2583277588","title":"BRIEF-SELLAS Life Sciences Q3 Net Income USD -6.791 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2583277588","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583277588?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981546,"startTime":"0","endTime":"0","summary":"BRIEF-SELLAS Life Sciences Q3 Net Income USD -6.791 Million\n\n\nNov 12 (Reuters) - SELLAS Life Sciences Q3 operating expenses USD 7.083 million.\n\nQ3 basic EPS USD -0.06\nQ3 operating income USD -7.083 million","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251112:nPLXF0C6DE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2583958899","title":"Press Release: SELLAS Life Sciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2583958899","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583958899?lang=en_us&edition=fundamental","pubTime":"2025-11-13 05:05","pubTimestamp":1762981500,"startTime":"0","endTime":"0","summary":"-- Hosted Virtual R&D Day Highlighting GPS and SLS009 Programs in AML --. -- Positive Phase 2 Data for SLS009 in R/R AML Accepted for Presentation at ASH 2025; Initiation of Trial Including Newly Diagnosed First-Line AML Patients Expected in Q1 2026 --. -- $44.3 Million in Cash and Cash Equivalents as of September 30, 2025; Additional $29.1 Million in Proceeds Received in October 2025 through Warrant Exercises --. Dr. Stergiou continued, \"Our recent R&D Day was a resounding success and provided an excellent opportunity to share program updates and hear directly from leading experts who expressed genuine enthusiasm for both GPS and SLS009. These achievements highlight the breadth and promise of our pipeline and underscore the complementary potential of our two programs to meaningfully improve outcomes for patients with AML and other hematologic cancers. With a strong financial foundation following the recent warrant exercises and multiple catalysts ahead, we believe SELLAS is entering a","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2463526074.USD","ASH","BK4139","BK4109","SLS"],"gpt_icon":0},{"id":"2583046623","title":"Sellas Life Sciences options imply 12.3% move in share price post-earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2583046623","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583046623?lang=en_us&edition=fundamental","pubTime":"2025-11-13 02:50","pubTimestamp":1762973418,"startTime":"0","endTime":"0","summary":"Pre-earnings options volume in Sellas Life Sciences (SLS) is normal with calls leading puts 142:1. Implied volatility suggests the market is antici...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-options-imply-12-3-move-in-share-price-post-earnings-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/sellas-life-sciences-options-imply-12-3-move-in-share-price-post-earnings-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["SLS","BK4139"],"gpt_icon":0},{"id":"2582735136","title":"Papa John's Is Not First: Here Are 3 Other Stocks Rocked By Market-Moving Fake News","url":"https://stock-news.laohu8.com/highlight/detail?id=2582735136","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582735136?lang=en_us&edition=fundamental","pubTime":"2025-11-11 16:33","pubTimestamp":1762849980,"startTime":"0","endTime":"0","summary":"Papa John's (PZZA) stock surged from a fake news hoax. It's not the first. See 3 other stocks, like Vinci & Avon, hit by market scams.","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/11/11/PapaJohns-storefront.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/11/11/PapaJohns-storefront.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/equities/25/11/48773842/papa-johns-is-not-first-here-are-3-other-stocks-rocked-by-market-moving-fake-news","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/equities/25/11/48773842/papa-johns-is-not-first-here-are-3-other-stocks-rocked-by-market-moving-fake-news","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["BK4139","AVP","LU2087625088.SGD","LU0353189763.USD","SLS","BK4209","LU0353189680.USD","PZZA","LU2065731478.USD"],"gpt_icon":0},{"id":"2581001300","title":"Sellas Life Sciences Group Inc  expected to post a loss of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581001300","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581001300?lang=en_us&edition=fundamental","pubTime":"2025-11-07 19:12","pubTimestamp":1762513938,"startTime":"0","endTime":"0","summary":"Sellas Life Sciences Group Inc  expected to post a loss of7cents a share - Earnings Preview Sellas Life Sciences Group Inc SLS.OQ SLS.O is expected to  show no change in quarterly revenue when it repo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ16S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","SLS"],"gpt_icon":0},{"id":"2580735690","title":"Ero Announces Result of Year-Long Value-Creation Initiative at Xavantina, Commences First Gold Concentrate Sales in Q4 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2580735690","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580735690?lang=en_us&edition=fundamental","pubTime":"2025-11-04 20:00","pubTimestamp":1762257600,"startTime":"0","endTime":"0","summary":"VANCOUVER, British Columbia, Nov.  04, 2025  (GLOBE NEWSWIRE) -- Ero Copper Corp. (TSX: ERO, NYSE: ERO) (\"Ero\" or the “Company”) is pleased to announce the results of a year-long effort to create addi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/04/3180153/0/en/Ero-Announces-Result-of-Year-Long-Value-Creation-Initiative-at-Xavantina-Commences-First-Gold-Concentrate-Sales-in-Q4-2025.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4015","BK4139","SLS","ERO"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.sellaslifesciences.com","stockEarnings":[{"period":"1week","weight":0.3275},{"period":"1month","weight":1.5133},{"period":"3month","weight":1.2047},{"period":"6month","weight":0.7373},{"period":"1year","weight":2.625},{"period":"ytd","weight":2.625}],"compareEarnings":[{"period":"1week","weight":-0.0123},{"period":"1month","weight":0.0024},{"period":"3month","weight":0.019},{"period":"6month","weight":0.0905},{"period":"1year","weight":0.1635},{"period":"ytd","weight":0.1635}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.","yearOnYearQuotes":[{"month":1,"riseRate":0.454545,"avgChangeRate":-0.033421},{"month":2,"riseRate":0.454545,"avgChangeRate":-0.042394},{"month":3,"riseRate":0.272727,"avgChangeRate":-0.053487},{"month":4,"riseRate":0.454545,"avgChangeRate":0.091111},{"month":5,"riseRate":0.727273,"avgChangeRate":0.118591},{"month":6,"riseRate":0.272727,"avgChangeRate":-0.198756},{"month":7,"riseRate":0.363636,"avgChangeRate":-0.033023},{"month":8,"riseRate":0.363636,"avgChangeRate":-0.058558},{"month":9,"riseRate":0.272727,"avgChangeRate":-0.031827},{"month":10,"riseRate":0.363636,"avgChangeRate":0.051142},{"month":11,"riseRate":0.25,"avgChangeRate":-0.061889},{"month":12,"riseRate":0.25,"avgChangeRate":0.046982}],"exchange":"NASDAQ","name":"SELLAS Life Sciences Group Inc.","nameEN":"SELLAS Life Sciences Group Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"SELLAS Life Sciences Group Inc.,SLS,SELLAS Life Sciences Group Inc.股票,SELLAS Life Sciences Group Inc.股票老虎,SELLAS Life Sciences Group Inc.股票老虎国际,SELLAS Life Sciences Group Inc.行情,SELLAS Life Sciences Group Inc.股票行情,SELLAS Life Sciences Group Inc.股价,SELLAS Life Sciences Group Inc.股市,SELLAS Life Sciences Group Inc.股票价格,SELLAS Life Sciences Group Inc.股票交易,SELLAS Life Sciences Group Inc.股票购买,SELLAS Life Sciences Group Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SELLAS Life Sciences Group Inc.(SLS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest SELLAS Life Sciences Group Inc.(SLS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}